MedTrace Logo

Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation

NCT06784466 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2026-04-08

No results posted yet for this study

Summary

To evaluate the safety and effectiveness of the Argá Medtech CSE Ablation System in the treatment of atrial fibrillation.

Conditions

  • Atrial Fibrillation (AF)
  • Persistant Atrial Fibrillation
  • Paroxysmal AF

Interventions

DEVICE

Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System

Ablation using the Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System

Sponsors & Collaborators

  • Arga Medtech SA

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-10
Primary Completion
2027-06-30
Completion
2027-08-31
FDA Device
Yes

Countries

  • United States
  • Belgium
  • Croatia
  • Czechia
  • Lithuania
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06784466 on ClinicalTrials.gov